Advanced Industrial Partners (AIP), a private equity firm focused on industrial and healthcare technology companies, has completed its acquisition of Avanos Medical, Inc. (NYSE: AVNS) for approximately $1.272 billion. The transaction, which was announced in late 2025, received all required regulatory approvals — including clearance from the Federal Trade Commission (FTC) under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act — and closed in mid-2026.

Avanos Medical, formerly known as Halyard Health, is a Alpharetta, Georgia-based medical device company specializing in pain management and respiratory health products. Its product portfolio includes the ON-Q pain relief system, COOLIEF cooled radiofrequency therapy for chronic pain, and a range of respiratory and digestive health devices. The company had approximately 1,700 employees and generated revenues of approximately $700 million in fiscal year 2025.

The acquisition price of $1.272 billion represents a premium of approximately 28% over Avanos's 30-day volume-weighted average share price prior to the announcement, and a transaction multiple of approximately 1.8x trailing twelve-month revenues.

All acquisitions of U.S. companies above the HSR threshold (currently $119.5 million for 2026) require pre-merger notification to the FTC and the Department of Justice (DOJ) Antitrust Division. The parties must observe a mandatory waiting period — typically 30 days — during which regulators may issue a "second request" for additional information if they identify potential competitive concerns.

In the Avanos/AIP transaction, the FTC's review focused on the pain management device segment, where Avanos holds meaningful market positions in cooled radiofrequency ablation and continuous nerve block systems. AIP's existing portfolio companies were examined for horizontal overlaps. The FTC ultimately cleared the transaction without conditions, finding that the combined entity would not substantially lessen competition in any relevant product market.

The Committee on Foreign Investment in the United States (CFIUS) reviews acquisitions of U.S. businesses by foreign persons for national security implications. While AIP is a U.S.-domiciled private equity firm, CFIUS jurisdiction can extend to transactions where foreign limited partners hold significant interests in the acquiring fund.

Medical device companies that supply products to the U.S. Department of Defense, Veterans Affairs, or other federal healthcare programs may qualify as "TID U.S. businesses" (Technology, Infrastructure, or Data businesses) subject to mandatory CFIUS filing requirements. Avanos's respiratory health products have historically been used in military and VA healthcare settings, which likely necessitated a CFIUS filing or at minimum a voluntary notice to confirm no national security concerns.

The transaction closed without CFIUS-imposed conditions, suggesting either that the mandatory filing threshold was not triggered or that CFIUS completed its review without identifying actionable national security concerns.

Unlike pharmaceutical acquisitions, medical device M&A does not require FDA approval of the transaction itself. However, the change of ownership of FDA-cleared or FDA-approved devices requires notification to the FDA and, in some cases, submission of new 510(k) premarket notifications or PMA supplements. AIP and Avanos will need to manage the regulatory transition of Avanos's device portfolio, including updating establishment registrations and device listings with the FDA.

Avanos had been a publicly traded company since its 2014 spin-off from Kimberly-Clark. As a standalone public company, Avanos faced persistent pressure from institutional investors focused on near-term earnings performance, limiting management's ability to invest in longer-cycle product development and international market expansion.

Private equity ownership removes this quarterly earnings pressure and provides capital for strategic investments that may not generate returns within a typical public company's planning horizon. AIP's industrial and healthcare technology focus suggests an investment thesis centered on operational improvement, product portfolio rationalization, and potential add-on acquisitions to build a larger pain management platform.

The U.S. pain management device market is undergoing significant structural change. The opioid crisis has created regulatory and social pressure to develop non-opioid pain management alternatives, and Avanos's COOLIEF and ON-Q systems are positioned as exactly such alternatives. Federal legislation — including the SUPPORT for Patients and Communities Act and subsequent opioid abatement frameworks — has created favorable reimbursement dynamics for non-opioid interventional pain procedures.

AIP's acquisition of Avanos reflects a broader private equity thesis that non-opioid pain management represents a durable growth market with favorable regulatory tailwinds.

For Turkish companies and investors considering acquisitions in the U.S. healthcare sector, the Avanos/AIP transaction illustrates the multi-layered regulatory review process that characterizes healthcare M&A:

Antitrust review under HSR is mandatory above the filing threshold and requires careful analysis of product market definitions, competitive overlaps, and potential remedies. Healthcare markets are frequently defined narrowly by regulators, meaning that even modest market shares in specialized product categories can attract scrutiny.

CFIUS review is increasingly relevant for healthcare transactions involving foreign acquirers. Medical device companies that supply federal healthcare programs, hold sensitive patient data, or develop dual-use technologies may be subject to mandatory CFIUS filing requirements regardless of the acquirer's nationality.

FDA regulatory transition requires advance planning. The transfer of device registrations, 510(k) clearances, and quality system certifications must be managed carefully to avoid disruptions to commercial operations.

The 1.8x revenue multiple paid for Avanos provides a useful benchmark for valuing medical device companies with established commercial products but moderate growth profiles. Higher-growth medtech companies with novel technologies typically command 4-8x revenue multiples, while mature device companies with commoditized products may trade at 1-1.5x revenues.

For Turkish investors evaluating U.S. healthcare acquisitions, understanding these valuation benchmarks — and the regulatory costs embedded in them — is essential for structuring competitive bids and realistic return projections.

Foreign acquirers of U.S. medical device companies must navigate several legal frameworks simultaneously:

Corporate acquisition structure: The choice between a stock purchase, asset purchase, or merger structure has significant implications for FDA regulatory continuity, liability assumption, and tax efficiency. Stock purchases preserve FDA clearances and registrations in the acquired entity but also transfer all historical liabilities. Asset purchases allow selective liability assumption but may require new FDA submissions.

Employment law: U.S. medical device companies typically have significant R&D and regulatory affairs workforces. Acquisitions trigger WARN Act notification requirements if the acquirer plans workforce reductions, and may require renegotiation of employment agreements with key technical personnel.

Intellectual property: Medical device IP portfolios — patents, trade secrets, regulatory data — are often the primary value driver. Thorough IP due diligence, including freedom-to-operate analysis and patent expiration schedules, is essential.

Reimbursement risk: Medical device revenues depend heavily on Medicare and Medicaid reimbursement rates, which are subject to regulatory change. Due diligence must include analysis of the acquired company's reimbursement profile and exposure to CMS rate-setting decisions.

The AIP acquisition of Avanos Medical demonstrates the continued appetite of U.S. private equity for specialized medtech assets with defensible market positions and favorable regulatory tailwinds. The transaction's clean regulatory clearance — no antitrust conditions, no CFIUS mitigation measures — reflects careful pre-signing diligence and a transaction structure designed to minimize regulatory friction.

For Turkish companies and investors active in the healthcare sector, this transaction provides a useful template for understanding the regulatory, structural, and valuation considerations that govern U.S. healthcare M&A. ULF New York advises Turkish clients on cross-border healthcare acquisitions, regulatory strategy, and transaction structuring in the U.S. market.

This analysis is provided for informational purposes only and does not constitute legal advice. Readers should consult qualified legal counsel regarding specific transactions or regulatory matters.